200 related articles for article (PubMed ID: 21781317)
21. BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression.
Kim SH; Ryu H; Ock CY; Suh KJ; Lee JY; Kim JW; Lee JO; Kim JW; Kim YJ; Lee KW; Bang SM; Kim JH; Lee JS; Ahn JB; Kim KJ; Rha SY
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30326563
[TBL] [Abstract][Full Text] [Related]
22. A new diaryl urea compound, D181, induces cell cycle arrest in the G1 and M phases by targeting receptor tyrosine kinases and the microtubule skeleton.
Zhang J; Zhou J; Ren X; Diao Y; Li H; Jiang H; Ding K; Pei D
Invest New Drugs; 2012 Apr; 30(2):490-507. PubMed ID: 21080210
[TBL] [Abstract][Full Text] [Related]
23. Imatinib blocks migration and invasion of medulloblastoma cells by concurrently inhibiting activation of platelet-derived growth factor receptor and transactivation of epidermal growth factor receptor.
Abouantoun TJ; MacDonald TJ
Mol Cancer Ther; 2009 May; 8(5):1137-47. PubMed ID: 19417143
[TBL] [Abstract][Full Text] [Related]
24. Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma.
Angevin E; Lopez-Martin JA; Lin CC; Gschwend JE; Harzstark A; Castellano D; Soria JC; Sen P; Chang J; Shi M; Kay A; Escudier B
Clin Cancer Res; 2013 Mar; 19(5):1257-68. PubMed ID: 23339124
[TBL] [Abstract][Full Text] [Related]
25. Anticancer effect of COX-2 inhibitor DuP-697 alone and in combination with tyrosine kinase inhibitor (E7080) on colon cancer cell lines.
Altun A; Turgut NH; Kaya TT
Asian Pac J Cancer Prev; 2014; 15(7):3113-21. PubMed ID: 24815456
[TBL] [Abstract][Full Text] [Related]
26. Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signaling.
Shigesawa T; Maehara O; Suda G; Natsuizaka M; Kimura M; Shimazaki T; Yamamoto K; Yamada R; Kitagataya T; Nakamura A; Suzuki K; Ohara M; Kawagishi N; Umemura M; Nakai M; Sho T; Morikawa K; Ogawa K; Ohnishi S; Sugiyama M; Mizokami M; Takeda H; Sakamoto N
Carcinogenesis; 2021 Feb; 42(1):58-69. PubMed ID: 32449510
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
[TBL] [Abstract][Full Text] [Related]
28. Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor.
Wang D; Tang F; Wang S; Jiang Z; Zhang L
Cancer Chemother Pharmacol; 2012 Jan; 69(1):173-83. PubMed ID: 21638122
[TBL] [Abstract][Full Text] [Related]
29. KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties.
Nakamura K; Taguchi E; Miura T; Yamamoto A; Takahashi K; Bichat F; Guilbaud N; Hasegawa K; Kubo K; Fujiwara Y; Suzuki R; Kubo K; Shibuya M; Isae T
Cancer Res; 2006 Sep; 66(18):9134-42. PubMed ID: 16982756
[TBL] [Abstract][Full Text] [Related]
30. The Tyrosine Kinase Inhibitor TAS-115 Attenuates Bleomycin-induced Lung Fibrosis in Mice.
Koyama K; Goto H; Morizumi S; Kagawa K; Nishimura H; Sato S; Kawano H; Toyoda Y; Ogawa H; Homma S; Nishioka Y
Am J Respir Cell Mol Biol; 2019 Apr; 60(4):478-487. PubMed ID: 30540913
[TBL] [Abstract][Full Text] [Related]
31. Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models.
Peng X; Hou P; Chen Y; Dai Y; Ji Y; Shen Y; Su Y; Liu B; Wang Y; Sun D; Jiang Y; Zha C; Xie Z; Ding J; Geng M; Ai J
J Exp Clin Cancer Res; 2019 Aug; 38(1):372. PubMed ID: 31438996
[TBL] [Abstract][Full Text] [Related]
32. Antitumour activity of oral E7080, a novel inhibitor of multiple tyrosine kinases, in human sarcoma xenografts.
Bruheim S; Kristian A; Uenaka T; Suo Z; Tsuruoka A; Nesland JM; Fodstad Ø
Int J Cancer; 2011 Aug; 129(3):742-50. PubMed ID: 21225632
[TBL] [Abstract][Full Text] [Related]
33. Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors.
Feng S; Shao L; Castro P; Coleman I; Nelson PS; Smith PD; Davies BR; Ittmann M
Oncotarget; 2017 Jan; 8(4):6179-6192. PubMed ID: 28008155
[TBL] [Abstract][Full Text] [Related]
34. Differential effects of red and white wines on inhibition of the platelet-derived growth factor receptor: impact of the mash fermentation.
Sparwel J; Vantler M; Caglayan E; Kappert K; Fries JW; Dietrich H; Böhm M; Erdmann E; Rosenkranz S
Cardiovasc Res; 2009 Mar; 81(4):758-70. PubMed ID: 19074160
[TBL] [Abstract][Full Text] [Related]
35. Effects of low concentrations of regorafenib and sorafenib on human HCC cell AFP, migration, invasion, and growth in vitro.
Carr BI; D'Alessandro R; Refolo MG; Iacovazzi PA; Lippolis C; Messa C; Cavallini A; Correale M; Di Carlo A
J Cell Physiol; 2013 Jun; 228(6):1344-50. PubMed ID: 23169148
[TBL] [Abstract][Full Text] [Related]
36. Over-expression of PDGFR-β promotes PDGF-induced proliferation, migration, and angiogenesis of EPCs through PI3K/Akt signaling pathway.
Wang H; Yin Y; Li W; Zhao X; Yu Y; Zhu J; Qin Z; Wang Q; Wang K; Lu W; Liu J; Huang L
PLoS One; 2012; 7(2):e30503. PubMed ID: 22355314
[TBL] [Abstract][Full Text] [Related]
37. Receptor tyrosine kinase inhibition by regorafenib/sorafenib inhibits growth and invasion of meningioma cells.
Tuchen M; Wilisch-Neumann A; Daniel EA; Baldauf L; Pachow D; Scholz J; Angenstein F; Stork O; Kirches E; Mawrin C
Eur J Cancer; 2017 Mar; 73():9-21. PubMed ID: 28082204
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of the novel selective platelet-derived growth factor receptor antagonist CT52923 on cellular proliferation, migration, and suppression of neointima following vascular injury.
Yu JC; Lokker NA; Hollenbach S; Apatira M; Li J; Betz A; Sedlock D; Oda S; Nomoto Y; Matsuno K; Ide S; Tsukuda E; Giese NA
J Pharmacol Exp Ther; 2001 Sep; 298(3):1172-8. PubMed ID: 11504817
[TBL] [Abstract][Full Text] [Related]
39. Fingolimod inhibits PDGF-B-induced migration of vascular smooth muscle cell by down-regulating the S1PR1/S1PR3 pathway.
Mousseau Y; Mollard S; Richard L; Nizou A; Faucher-Durand K; Cook-Moreau J; Qiu H; Baaj Y; Funalot B; Fourcade L; Sturtz FG
Biochimie; 2012 Dec; 94(12):2523-31. PubMed ID: 22828274
[TBL] [Abstract][Full Text] [Related]
40. SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity.
Patyna S; Laird AD; Mendel DB; O'farrell AM; Liang C; Guan H; Vojkovsky T; Vasile S; Wang X; Chen J; Grazzini M; Yang CY; Haznedar JO; Sukbuntherng J; Zhong WZ; Cherrington JM; Hu-Lowe D
Mol Cancer Ther; 2006 Jul; 5(7):1774-82. PubMed ID: 16891463
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
